Congruently, there are currently 40 multidistrict litigations pending with the judicial panel on multidistrict litigation in which plaintiffs allege the defendants engaged in false and misleading marketing and sales practices, including those for vioxx, tylenol, celexa, lipitor, avandia and plavix, to name a few.